NIBIB Payline 2026: No Cutoff and a 16.1% New R01 Rate

The NIH and NSF funding odds tracker puts NIBIB next to every other institute.

People searching "NIBIB payline" usually want one number. NIBIB gives a different kind of answer: it tells you exactly how it trims the budget and the project length once you're picked, but not where the pick happens.

NIBIB Payline Status: 0 Cutoffs, 2 Budget Rules

NIBIB lists 0 percentile or impact-score cutoffs on its FY2026 funding policy page (opens in a new tab). The page says NIBIB "will prioritize scientific merit when making funding decisions" and names the other factors it weighs: program priorities, investigator career stage, investigator funding levels, overall portfolio balance and available funds.

That fits the NIH-wide shift. NIH's funding decisions page (opens in a new tab) says institutes "will no longer employ these cutoff points in overall impact scores to determine which applications to fund." NIBIB also says it aims to fund "the largest number of meritorious projects possible" while keeping room for its own programs and the Unified Funding Strategy.

What NIBIB does publish is unusually concrete on money:

The page header also notes that NIH is operating under a continuing resolution (NOT-OD-26-131), so FY2027 decisions may run on a different budget than FY2026's.

NIBIB R01 Success Rates, FY2019 to FY2025

From FY2019 to FY2024, NIBIB's new R01 success rate stayed between 18.3% and 24.2%. FY2025 dropped to 16.1%. The figures below come from NIH's success-rate tables (opens in a new tab).

NIBIB's FY2025 drop has a different cause than at many institutes. Awards actually rose, from 73 new R01s to 88. Applications rose much faster, from 365 to 545, an increase of 180 in one year. More applicants chasing a slightly larger pool pushed the rate down.

According to NIH Data Book table 217, NIBIB's rate across all research project grants fell from 16.1% (175 of 1,084) in FY2024 to 12.8% (188 of 1,464) in FY2025. The same jump in volume shows up there: 380 more applications.

For context, NIH funded 9.9% of new R01 applications across all institutes in FY2025 (3,405 of 34,491), so NIBIB stayed above the NIH average.

Three points to keep straight when reading these rates:

• A success rate isn't a payline. It divides awards by all applications reviewed, including unscored ones. The share of discussed NIBIB applications that got funded was higher than 16.1%.
• A1 and A0 in the same year count once. NIH's success rate definition (opens in a new tab) treats an application and its resubmission in the same fiscal year as one.
• R56 bridges count as funded. An R01 that wasn't funded but later received an R56 counts as a funded application.

What the 10% and 20% Average Cuts Mean

NIBIB cuts every parent R01 it funds: by an average of 10% for ESI and modular applications and 20% for non-modular applications from established investigators. The policy page says reductions depend on "comments in the summary statement, availability of other support, and program priorities," so your cut can be larger or smaller than the average.

A hypothetical illustration: a non-modular request of $400,000 a year cut by the 20% average would come in near $320,000. The same request from an ESI, or a modular request, would land closer to 90% of what was asked. Both are averages, not guarantees.

Applicants underestimate this rule in two ways:

1. They budget the science at 100%. If your aims only work at the full requested amount, a 20% trim forces you to drop or shrink an aim after award. Build a version of the plan that survives the cut.
2. They skip the modular option. The 10% average applies to modular requests regardless of career stage. If your project fits under the modular ceiling, the modular budget guide explains how to build one.

The Data Book money lines show what NIBIB actually paid. R01 and R37 funding rose from $44.7 million in FY2024 to $63.7 million in FY2025, and the average award climbed from $525,913 to $630,366. Some of that reflects awards paid several years at once (see the RePORTER section below).

The Four-Year Limit Shows Up in the Records

RePORTER shows 83 of 87 new FY2026 NIBIB R01 and R37 award records with four-year project periods. Grantsights analysis of NIH RePORTER records pulled November 8, 2026 found the same pattern in earlier years:

The four-year rule is close to absolute: just 2 of the 87 FY2026 records ran five years. If you're writing a five-year timeline for a parent R01 headed to NIBIB, rewrite it for four.

The $500,000 line is softer than "rare" suggests. In FY2026, 12 of 80 single-year awards had first-year direct costs of $500,000 or more. That's 15%, not zero. Still, NIBIB says those cases need to be highly compelling, and it encourages applicants to contact a program director before submitting to confirm mission relevance and program priority.

Multi-year funding grew. NIBIB paid 7 new FY2026 R01s several years up front, with a median total of $2,719,451, against 0 such awards in FY2024. NIH's FY2025 by-the-numbers post (opens in a new tab) said changes "were likely due in part to more awards being forward funded than previous years." The FY2026 fiscal policy notice (opens in a new tab) sets this year's rules.

The red flag in this table: 87 FY2026 awards isn't a success rate. RePORTER lists funded grants, not the applications behind them. NIH hasn't released FY2026 Data Book rates, and Grantsights doesn't estimate them.

When NIBIB Awards Go Out

In FY2026, 28 of 87 new NIBIB R01 notices were issued in August and 16 in September, so roughly half arrived in the last two months of the fiscal year. FY2025 peaked earlier, with 28 notices in July and 17 in August.

A long quiet stretch after council isn't a no. It does mean you shouldn't wait for a funding decision before planning a resubmission if the summary statement flags fixable problems. The resubmission guide covers the A1.

Award geography also shifted. Massachusetts led new NIBIB R01 awards in FY2024 (12) and FY2025 (16). In FY2026, California led with 14 and Texas followed with 8. The University of Pennsylvania had the most FY2026 awards of any single institution, with 4.

NIBIB R21, R03 and R56 Odds

NIBIB's R21 success rate was 7.2% in FY2025, according to NIH Data Book table 206 (54 of 746 applications). That's less than half its 16.1% rate for new R01s.

For example, NIBIB received 746 R21 applications in FY2025, up from 590, and funded fewer of them. A common mistake is treating the R21 as the safer first step at NIBIB. On these numbers it's the harder one. The NIH R21 success rate page compares every institute, and the R21 award history shows recent R21 winners.

The R03 looks better on paper, but the pool is small: 66 applications in FY2025. Check that NIBIB participates in the R03 notice you'd use before relying on that rate; the R03 success rate page has the NIH-wide view.

R56 counts are tiny. NIBIB's policy page says it will consider one-year R56 bridge funding for meritorious-but-unfunded R01 applications, to support work toward a resubmission. Table 206 counts 12 NIBIB R56 awards in FY2022, 4 in FY2024 and 1 in FY2025. Treat a bridge as possible, not likely.

Fellowships and K Awards at NIBIB

NIBIB's K99 rate rose to 31.0% in FY2025 (9 of 29), from 26.3% in FY2024, according to NIH Data Book table 204. It's NIBIB's largest career pool, and other pools are too small to read alone.

NIBIB reviews very few fellowship applications, so a single award moves the rate by double digits. For broader comparisons, see the K award success rates by institute, the F31 success rate by institute and the F32 success rate page.

What NIBIB's Policy Page Doesn't Tell You

NIBIB's page answers the budget question well and leaves 4 others open:

First, it doesn't say what share of the 10% and 20% averages is negotiable. The cut depends on the summary statement, your other support and program priorities, so ask the program officer what drove the number before you accept a revised budget.

Second, it lists priority groups without saying how much weight each gets. Early-stage investigators, new investigators, first renewals of NIBIB ESI awardees, and established investigators who'd otherwise lose all substantial funding next year are all named. NIBIB publishes no separate ESI success rate, and the Data Book rows here don't split by career stage. The new investigator guide explains how to confirm ESI status.

Third, a strong application still fails because of fit. NIBIB's mission is enabling technology for the broader biomedical community. A project that uses imaging or engineering as a tool for a disease question may belong at a disease institute, and NIBIB says it weighs portfolio balance.

Fourth, the page doesn't explain the R21 gap. Grantsights checked the FY2026 policy text against table 206 and found no stated R21 restriction, yet the FY2025 R21 rate was 7.2%. The honest reading: the R21 at NIBIB was heavily oversubscribed in FY2025, and nothing on the policy page tells you that.

Submit, Rebudget, or Redirect: Decision Table

For the NIH-wide picture, read NIH paylines explained, the NIH R01 success rate data and the summary statement guide. Federal and foundation funding for engineering and device research beyond NIH is searchable in Grantsights grant search.

Sources

• NIBIB FY2026 funding policies and considerations (opens in a new tab)
• NIH funding decisions and the Unified Funding Strategy (opens in a new tab)
• NIH Data Book success-rate tables (opens in a new tab) (tables 203, 204, 206 and 217)
• NIH success rate definition (opens in a new tab)
• NIH, Fiscal Year 2025 By the Numbers (opens in a new tab)
• NOT-OD-26-059, Notice of Fiscal Policies in Effect for FY 2026 (opens in a new tab)
• NIH RePORTER (opens in a new tab) and the RePORTER API (opens in a new tab)

Related Guides

• NIH paylines explained
• NIH R01 success rate data
• NIH modular budget guide
• NIH R21 success rate
• How to resubmit an NIH grant